TNGX Live signals | Maximize Profits with Getagraph.com

SELL 103638 min ago

@ $11.71

Issued: 13 Feb 2024 @ 15:42

Return: -37.40%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -1.76 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	338 241
Average Volume	602 743
Market Cap	782.24M
EPS	$0 ( 2024-03-25 )
Next earnings date	( $-0.310 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.79
ATR14	$0.0130 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	Third Rock Ventures Iv, L.p.	Sell	162 500	Common Stock
2024-02-06	Weber Barbara	Sell	4 681	Common Stock
2024-02-07	Weber Barbara	Sell	4 457	Common Stock
2024-02-06	Barry Douglas	Sell	1 422	Common Stock
2024-02-07	Barry Douglas	Sell	1 354	Common Stock

INSIDER POWER
91.90
Last 93 transactions
Buy: 16 052 308 \| Sell: 885 960

Volume Correlation

Long: 0.04 (neutral)

Short: -0.61 (weak negative)

Signal:(39.757) Neutral

Tango Therapeutics, Inc. Correlation

10 Most Positive Correlations
GSMG	0.949
CMLS	0.947
AADI	0.942
AKTX	0.938
DSWL	0.934
ACRX	0.928
AROW	0.927
ALHC	0.926
ESSA	0.925
FGBI	0.923

10 Most Negative Correlations
MORF	-0.946
INOD	-0.93
INTA	-0.925
PLYA	-0.923
MOTNU	-0.917
ITI	-0.914
AMPH	-0.913
PESI	-0.912
WIRE	-0.912
VRCA	-0.911

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tango Therapeutics, Inc. Correlation - Currency/Commodity

0.20
( neutral )

0.39
( neutral )

0.00
( neutral )

-0.43
( neutral )

-0.34
( neutral )

Tango Therapeutics, Inc. Financials

Annual	2023
Revenue:	$36.53M
Gross Profit:	$34.11M (93.39 %)
EPS:	$-1.080

Q4	2023
Revenue:	$5.43M
Gross Profit:	$4.81M (88.64 %)
EPS:	$-0.320

Q3	2023
Revenue:	$10.73M
Gross Profit:	$10.12M (94.29 %)
EPS:	$-0.230

Q2	2023
Revenue:	$14.60M
Gross Profit:	$13.09M (89.67 %)
EPS:	$-0.230

Financial Reports:

No articles found.

Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.